Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc.
Your view on ZEOX
Overview
What the company does, where it operates, and who runs it.
About Zeo ScientifiX, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ian T. Bothwell
- Headquarters
- 3321 College Avenue, Davie, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ian T. Bothwell
- Headquarters
- 3321 College Avenue, Davie, FL, US
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines.
The company's lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis.
It also provides Patient Pure X, an autologous blood-derived biologic technology, that helps the body's natural ability to decrease cellular inflammation and promote tissue healing.
In addition, the company develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; ZEO GROW X, a professional-grade formula that delivers a concentrated dose of topical exosomes that help support follicular function; ZEO GROW BOOST; and EXO FOLLICLE FUEL.
The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in February 2024. Zeo ScientifiX, Inc. was incorporated in 2011 and is headquartered in Davie, Florida.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Zeo ScientifiX, Inc., and the rating behind it. ZEOX last traded at $2.41; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Zeo ScientifiX, Inc.. Starting points for Zeo ScientifiX, Inc.: EPS -$0.50, beta 3.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Zeo ScientifiX, Inc.. Zeo ScientifiX, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Zeo ScientifiX, Inc.. Trailing twelve-month EPS for Zeo ScientifiX, Inc. stands at -$0.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Zeo ScientifiX, Inc.. Zeo ScientifiX, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Zeo ScientifiX, Inc. valued side by side against its closest peers. Zeo ScientifiX, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Zeo ScientifiX, Inc., and how their positions are changing. At a $15.4M market value, institutional positions materially move Zeo ScientifiX, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Zeo ScientifiX, Inc. executives and directors. Shares of Zeo ScientifiX, Inc. have traded between $1.20 and $3.32 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Zeo ScientifiX, Inc.. Zeo ScientifiX, Inc. is a $15.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Zeo ScientifiX, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Zeo ScientifiX, Inc.. Coverage tracks Zeo ScientifiX, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.